ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Clinical trials for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial aims to turn Patients' own cells against rare, aggressive cancers
Disease control Recruiting nowThis early-stage trial is testing the safety of a new gene therapy for adults with certain T-cell lymphomas that have returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to target a protein (CCR4) foun…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill challenges standard care for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing an experimental oral drug called soquelitinib against standard chemotherapy options for adults with specific aggressive T-cell lymphomas that have returned or not responded to prior treatment. About 150 participants will be randomly assigned to receive eithe…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New IV drug trial offers hope for patients with aggressive lymphoma
Disease control Recruiting nowThis is an early-stage study testing a new intravenous drug called ST-001 for people with T-cell lymphoma that has come back or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug works in the body. It is for adults whos…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: SciTech Development, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC